Dasminapant

N/A

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameDasminapant
Drug Alias NameAPG-1387SM-1387
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of apoptosis proteins inhibitors
TargetsInhibitor of apoptosis proteins
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Ascentage Pharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAscentage Pharma Group IncClover Biopharmaceuticals Ltd
Inactive CompaniesGuangzhou Shunjian Biomedical Technology Co LtdJiangsu Ascentage Pharma Co Ltd
Active IndicationsSolid tumoursHepatitis B, ChronicHepatitis B
Inactive IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A